MyMD Pharmaceuticals Inc (MYMD)

[knuts4oe]

With MYMD trading in the $5.00 range at a time when its outlook appears to look awesome, we need to look elsewhere for the silver lining. That may be in the area of the relationships it has formed.
To begin with, MYMD's corporate office is located in a building owned by Johns Hopkins, which is located on the Johns Hopkins campus, and whose dedication includes nuturing small companies working on medical breakthroughs! We know from previous news releases that much of what we know about MYMD-1 was provided by Johns Hopkins researchers, and we know from a recent news release that Johns Hopkins is a leader in R and D research.
https://hub.jhu.edu/2021/02/09/nsf-research-development-funding-rankings-2019/
Next, we know that MYMD has apparently formed a cozy relationship with The Arthritis Foundation, evidenced 1st by its selection of MYMD's President, Chris Chapman, as its "Medical Honoree of 2021", and 2nd by the fact that following an MYMD presentation at the Arthritis Foundation in early 2022, MYMD will begin writing protocols for a Phase 2 pilot study of MYMD-1 for rheumatoid arthritis, hopefully financially supported by The Arthritis Foundation.
Additionally, the rheumatoid arthritis study will be undertaken with the assistance of IQVIA, a global company focussed on driving healthcare forward. Chris Chapman was hired by Quintiles, now known as IQVIA, in 1995 where he grew a division from no employees to 40 employees, including 8 physicians, before moving on in 2003. Jude Uzonwanne, a Director, was also an IQVIA employee at one point in his career.
Alison O'mahony, a Scientific Advisory Board member, is an employee of Eurofins Discovery, an international supporter of drug discovery. It was they, that determined that MYMD-1 was anti-prolific, anti-fibrotic, and performed as an JAK blocker equal to the 3 leading JAK blockers.
All in all MYMD has done an excellent job of developing support relationships that enhance its potential for success!